Molecular Tumor Board: 82-year-old female with high grade ovarian serous adenocarcinoma and BRCA1 F709fs mutation

An 82-year-old with advanced high-grade serous ovarian cancer and a BRCA1 mutation highlights the importance of somatic and germline testing to guide therapy and using PARP inhibitors for maintenance. Join our Molecular Tumor Board to explore treatment strategies and the impact of reversion mutations on resistance management.

Graphical Summary: Comprehensive NGS profiling to enable detection of ALK gene rearrangements and MET amplifications in non-small cell lung cancer

Molecular Tumor Board: 38-year-old female with follicular thyroid cancer and NRAS Q61R alteration

In our latest molecular tumor board, our Medical Affairs team conducted an in-depth review of a case of follicular thyroid cancer with an NRAS mutation. Our team delved into the critical role of molecular profiling to identify the major oncogenic mechanisms driving thyroid carcinogenesis and emphasized the importance of thorough pathological and imaging evaluations for an accurate diagnosis of thyroid cancer.

Comprehensive genomic and immune profiling for the detection of clinically significant tumor biomarkers

Analytical validation of OmniSeq® INSIGHT whole transcriptome sequencing assay to facilitate precision oncology through tumoronly testing in solid tumors

Analytical validation of OmniSeq® INSIGHT whole exome sequencing assay to facilitate precision oncology through tumor only testing in solid tumors

Validation of automated nucleic acid extraction using Covaris® Gen3 extraction methodology on the Assay-Ready Workstation

Enabling Access to Genomic Profiling through Decentralized Liquid Biopsy Solution PGDx elioTM plasma focus Dx

Molecular Tumor Board: 58-year-old male with breast carcinoma and BRCA2 R3128* mutation

Though less common than in women, understanding male breast cancer and symptoms can lead to earlier detection and improved outcomes.

Labcorp Perspectives: Optimizing biomarker testing in advanced NSCLC: Insights on comprehensive genomic profiling (CGP)

In the latest episode of Labcorp Perspectives: Oncology, Dr. Rebecca Ann Previs and Dr. Kyle Strickland, directors of medical affairs at Labcorp Oncology, delve into the significant advantages of comprehensive genomic profiling (CGP) over single-gene testing in patients with advanced non-small cell lung cancer (NSCLC). This study, using OmniSeq® INSIGHT, showed that CGP enables that patients with NSCLC to be tested for all recommended biomarkers at once, providing the best chance of identifying effective treatment options.